CN104547111A - Traditional Chinese medicinal composition for treating prosopalgia and induced sleep disorders and method for preparing composition - Google Patents

Traditional Chinese medicinal composition for treating prosopalgia and induced sleep disorders and method for preparing composition Download PDF

Info

Publication number
CN104547111A
CN104547111A CN201410847968.8A CN201410847968A CN104547111A CN 104547111 A CN104547111 A CN 104547111A CN 201410847968 A CN201410847968 A CN 201410847968A CN 104547111 A CN104547111 A CN 104547111A
Authority
CN
China
Prior art keywords
parts
chinese medicine
medicine composition
radix
traditional chinese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410847968.8A
Other languages
Chinese (zh)
Other versions
CN104547111B (en
Inventor
曾子维
罗永温
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201410847968.8A priority Critical patent/CN104547111B/en
Publication of CN104547111A publication Critical patent/CN104547111A/en
Application granted granted Critical
Publication of CN104547111B publication Critical patent/CN104547111B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to the field of traditional Chinese medicine, and relates to a traditional Chinese medicinal composition for treating prosopalgia and induced sleep disorders and a method for preparing the composition. Aiming at the deficiencies in the prior art that currently the chemotherapeutant for prosopalgia and induced sleep disorders is high in hepatotoxicity, and the curative effect is poor, the traditional Chinese medicinal composition for treating prosopalgia and induced sleep disorders is provided by the invention. The composition includes the following constituents in parts by weight: 15 parts of herbs, 15 parts of Chinese angelica, 6 parts of fallopian multiflora, 10 parts of agrimonia pilosa, 10 parts of eclipta prostrate, 6 parts of ginkgo biloba, 8 parts of semen ziziphi spinosae, 10 parts of angelica dahurica, 20 parts of polygonum cuspidatum, 20 parts of cassia twig, 10 parts of astragalus membranaceus, 5 parts of radix salvia miltiorrhizae, 5 parts of oysters and 10 parts of concha haliotidis. The traditional Chinese medicinal composition has a quite good curative effect in treating prosopalgia and induced sleep disorders, with fewer side effects and remarkable clinical popularization values.

Description

Treatment trigeminal neuralgia merges Chinese medicine composition of sleep disorder and preparation method thereof
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of trigeminal neuralgia for the treatment of and merge Chinese medicine composition of sleep disorder and preparation method thereof.
Background technology
Chronic pain often brings very heavy burden to patient, and cause its quality of life to decline, sleep reduces, daily routines are affected, long-term chronic pain also can make patient produce depression and anxiety.In some chronic pain patient, as fibromyalgia, rheumatism class pain etc., sleep disorder is often had outstanding performance, and has the people of 50% ~ 70% to there are sleeping problems according to the literature in chronic pain patient.Primary trigeminal neuralgia is one of typical chronic pain, its prevalence average out to 4,/10 ten thousand ~ 5,/10 ten thousand, and the cause of disease it be unclear that, the degree of pain is often relatively more serious, and stage of attack outbreak is frequent, and the increase side effect with drug dose also increases, tolerance declines, and pain degree also strengthens gradually.Research finds, primary trigeminal neuralgia patient exists sleep disorder, and appearance and the order of severity of the quality of sleep quality and the degree of pain, depression with anxiety are relevant, is also single-shot or multiple relevant with the position that pain occurs; Have nothing to do statistically with age, sex, education degree, income, marriage situation, complication situation etc.Pain therapy theory up-to-date at present often pursues multi-disciplinary intervention.
In clinical at present, a lot of patient selects conservative drug treat, although solve the problem of pain, not to for a long time and the sleeping problems deposited, depressive anxiety problem give therapeutic intervention.The Western medicine of current clinical treatment sleep disorder mostly is antipsychotics, adopt sedative hypnotic Drug therapy clinically, common drug is benzodiazepine, as diazepam, barbital, secobarbital etc., but such medicine is easy addiction not only, and long-term taking can cause huge infringement to the Liver and kidney of body, poisonous side effect of medicine is large.Existing clinical application experience shows, research and develop a kind of trigeminal neuralgia merge sleep disorder effective medicine for alleviating patient suffering, raising labour efficiency is of great practical significance.
CN101721600A discloses one and treats neurasthenic Chinese medicine composition, and it is that raw material is made by the Radix Rehmanniae, Semen Ziziphi Spinosae, Fructus Schisandrae Chinensis, the Rhizoma Anemarrhenae, Poria, Radix Polygalae, and its therapeutic effect is better, and effective percentage is up to more than 75%.CN101485864B discloses one and treats neurasthenic Chinese medicine composition, and it, get Semen Ziziphi Spinosae 20 grams, Caulis Polygoni Multiflori 15 grams, Semen Platycladi 12 grams, Radix Polygalae 7 grams, Poria cum Radix Pini 15 grams, Flos Albiziae 15 grams, 12 grams, Poria, the Radix Paeoniae Alba 12 grams, Radix Curcumae 9 grams, Radix Bupleuri 15 grams, 15 grams, the Radix Rehmanniae, Dens Draconis 20 grams and Pericarpium Citri Reticulatae Viride 9 grams of co-grinding to 200 orders, be then put into the medicine of pulverizing in the mixture of 60 grams of refined honeys and 50 grams of Radix Et Caulis Acanthopanacis Senticosi extractums and stir, finally make the pill of every 2-3 gram.Its soothing liver-QI for relieving depression, YIN nourishing Fructus Alpiniae Oxyphyllae, tranquillizing and allaying excitement is treatment concept, achieves good therapeutic effect.
Summary of the invention
The deficiency of sleep disorder clinical treatment medicine is merged for current trigeminal neuralgia, first object of the present invention is to provide a kind of Chinese medicine composition for the treatment of trigeminal neuralgia and merging sleep disorder, this Chinese medicine composition has when treating trigeminal neuralgia and merging sleep disorder the treatment advantage that therapeutic effect is remarkable, side effect is little, permanence operation is good, has fine medical application prospect.Chinese medicine composition of the present invention, according to components by weight percent meter, it obtains primarily of the raw material of following weight portion: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, Concha Haliotidis 10 parts.
Chinese medicine in Chinese medicine composition of the present invention is got its conventional medicinal part and is used as medicine.The mutual compatible combination of said medicine in the present invention, complements one another, and reaches the object of tranquilizing by nourishing the heart, anti-inflammatory and antalgic and soothing liver-QI for relieving depression, and merging sleep disorder to trigeminal neuralgia has good curative effect.6 parts, Radix Rehmanniae Preparata, Herba Epimedii 12 parts, Galla Chinensis 8 parts can also be contained in the present invention's Chinese medicine composition described above.Radix Rehmanniae Preparata, Herba Epimedii, Galla Chinensis three kinds of medicines are used in conjunction, not only can the immunocompetence of remarkable enhancing body, and three kinds of medicines and aforementioned pharmaceutical compositions coupling of the present invention can strengthen its therapeutic effect trigeminal neuralgia being merged to sleep disorder further.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, adds the 5-15 water doubly of medical material gross weight, soaks 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.The above-mentioned Chinese medicine composition of the present invention can be prepared into pharmaceutical preparation conventional clinically further, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, and namely above-mentioned Chinese medicine composition merges the purposes in sleep disorder remedies at preparation treatment trigeminal neuralgia.The embodiment of the present invention 7 is tested the impact of free moving rats sleep phases by investigating Chinese medicine composition of the present invention, find that Chinese medicine composition of the present invention all can extend SWS2 and the REMS time with positive controls compared with model group, and reduce the wake time, wherein each group of Chinese medicine composition of the present invention has pole significant difference compared with model group in prolongation SWS2 and REMS time and reduction Wake time, also has significant difference compared with positive controls.Chinese medicine composition of the present invention presents dose dependent in prolongation SWS2 and REMS time and reduction Wake time.The embodiment of the present invention 8 shows, all there is significant rising the threshold of pain of the different time sections in carbamazepine group and each traditional Chinese medicine composition for treating group relative to model group, embody prosopalgic therapeutical effect, wherein each dosage group of Chinese medicine has pole significant difference (P < 0.01) compared with model group, also has the difference (P < 0.05) of significance compared with conventional trigeminal neuralgia medicine carbamazepine group.Chinese medicine composition is better at treatment effects in treating trigeminal neuralgia, and presents dose dependent, and Chinese medicine composition of the present invention is to prosopalgic Long term therapy better effects if.
In a word, the present invention compared with prior art, has treatment trigeminal neuralgia very well and merge the activity of sleep disorder, and the present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention merges treatment of sleep disorders drug use as trigeminal neuralgia, drug effect is comprehensive, while dispersing the stagnated live-QI to relieve the stagnation of QI, anti-inflammatory and antalgic, activating blood circulation to dissipate blood stasis can also be obtained, effect that calming blood is calmed the nerves, the mutual compatible combination of ladies and gentlemen's medicine, complements one another, and plays synergism, heart tonifying, the kidney invigorating can be reached, calm the nerves, heat clearing away, the object such as enhancing immunologic function, prevention and therapy insomnia, agitation, dizziness, dreaminess, absent minded, hypomnesis etc. have good effect; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good application prospect.
Detailed description of the invention
Further describe the present invention below by way of detailed description of the invention, but the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, Chinese medicine composition of the present invention is suitably improved, replaces the identical component of effect, will become apparent to those skilled in the art that they are all deemed to be included within scope of the present invention.
part I, the preparation of Chinese medicine composition of the present invention
embodiment 1 Chinese medicine composition mixture of the present invention
Prescription: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, Concha Haliotidis 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 2 Chinese medicine composition mixture of the present invention
Prescription: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, 6 parts, Concha Haliotidis 10 parts of Radix Rehmanniaes Preparata, Herba Epimedii 12 parts of Galla Chinensiss 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 5 times of medical material gross weight, soaks 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.1, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 75%(v/v), leave standstill 24 hours, get supernatant, recovery ethanol concentrates, and adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 3 Chinese medicine composition tablet of the present invention
Prescription: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, Concha Haliotidis 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 4 Chinese medicine composition tablet of the present invention
Prescription: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, 6 parts, Concha Haliotidis 10 parts of Radix Rehmanniaes Preparata, Herba Epimedii 12 parts of Galla Chinensiss 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 10 times of medical material gross weight, soaks 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 80%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
embodiment 5 Chinese medicinal composition capsules agent of the present invention
Prescription: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, Concha Haliotidis 10 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
embodiment 6 Chinese medicinal composition capsules agent of the present invention
Prescription: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, 6 parts, Concha Haliotidis 10 parts of Radix Rehmanniaes Preparata, Herba Epimedii 12 parts of Galla Chinensiss 8 parts.
Preparation method: each medical material getting above-mentioned components by weight percent, adds the water of 8 times of medical material gross weight, soaks 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.2, and this relative density is testing result at 60 c, adding ethanol to alcohol content is 90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
part II, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
embodiment 7 Chinese medicine composition of the present invention is on the impact on free moving rats sleep phases
1, modelling
Adopt pentobarbital sodium by after rat anesthesia (40mg/kg, ip), fix with brain solid positioner, head cropping, after sterilization, cut off skin of head, fully expose skull, peel off periosteum.Respectively at (AP-2, R2 on skull; AP+2, R2) boring, 2 diameter 1mm CARBURIZING FURNACE FOR STAINLESS FASTENER nails are implanted in skull, makes it to contact with cerebral dura mater, but do not penetrate cerebral dura mater, as cortical electrode; Settle ground electrode in frontal bone center (AP+5, R0) boring, and electrode screw is made mini jack, fix with dental cement.Postoperatively laboratory animal to be placed in special lucite cylinder, to be placed in single cage in screened room and to raise.Continuous 3d,ip4 ten thousand units of Penicillin, recovers 7d to be measured.Before formally carrying out brain electricity and tracing, the plug with wire is connected with rat head electrode socket, carries out the acclimatization training that rat connects electrode socket, training 4.5h.Rat after surgery recovery 24 is divided at random hundred wheats to calm the nerves electuary low dose group, middle dosage group, high dose group.
2, laboratory animal grouping and administration
Rat after surgery recovery 50 is divided into model group, positive controls at random, group, Chinese medicine composition object height group in low group of Chinese medicine composition, Chinese medicine composition.Postoperative 8d gives the CMC-NA solution of 0.5% of 3 groups of rats and dose equal volume, brain electricity (EEG) signal of the free moving rats before record administration.The time of tracing is 9:00-17:00, amounts to 8h.Morning next day, 8:30 gave laboratory animal following medicine through ig respectively, successive administration 7d, after last administration 30min, then traced the brain electricity that rat carries out 8h.
Model group: gavage gives isopyknic distilled water
Positive controls: gavage gives Chinese medicine in CN101485864B detailed description of the invention, dosage is 1g/kg;
Low group of Chinese medicine: gavage gives Chinese medicine composition described in the embodiment of the present invention 1, dosage is 0.5g/kg;
Group in Chinese medicine: gavage gives Chinese medicine composition described in the embodiment of the present invention 1, dosage is 2g/kg;
Chinese medicine high group: gavage gives Chinese medicine composition described in the embodiment of the present invention 1, dosage is 8g/kg;
3, observation index and data analysis
According to rat brain electrograph, and rat awakening-sleep cycle is divided into awakening (Wake), S sleep I phase (SWSl), S sleep II phase (SWS2) and REM sleep (REMS) 4 phases with reference to related documents.Calculate this respectively and to trace in the time period senior middle school's low dose group normal rat Wake before and after administration, SWSI, SWS2, REMS, TST(sleep total time) in respective total time.Experimental result represents with mean ± standard deviation, and application self pair t method of inspection carries out statistical analysis.
4, experimental result
Table 1 Chinese medicine composition of the present invention is on the impact of free moving rats sleep phases
Compare with model group, *p < 0.05, *p < 0.01;
As can be seen from Table 1, Chinese medicine composition of the present invention and positive controls all can extend SWS2 and the REMS time compared with model group, and reduce the wake time, wherein each group of Chinese medicine composition of the present invention has pole significant difference compared with model group in prolongation SWS2 and REMS time and reduction Wake time, also has significant difference compared with positive controls.Chinese medicine composition of the present invention presents dose dependent in prolongation SWS2 and REMS time and reduction Wake time.
embodiment 8 Chinese medicine composition of the present invention is to the therapeutical effect of trigeminal neuralgia of rats model
1, the foundation of laboratory animal animal model
Adult male SD rats, 200 ~ 250g/ only.After measuring preoperative pain threshold value (based on the threshold of pain), carry out left side nervus infraorbitalis (Infraorbitalnerve, ION) cerclage.Observe animal after 2 weeks and whether occur allodynia phenomenon, the person of appearance is elected to, totally 50.
According to Ding Lihua (Ding Lihua, Yu Shengyuan. experimental trigeminal neuralgia chronic constriction ring art Animal Model. Chinese pain medicine magazine, 2004,10:15 ~ 18) method that provides makes one-sided (left side) ION-CCI nervi trigeminus pain model.Specific as follows: laboratory animal is with 10% chloral hydrate (0.4ml/100g) intraperitoneal injection, after anesthesia is satisfied, lie on the back fixing, in Mus oral cavity, along gum cheek edge, left side, flat first molar level, longitudinally the long otch of about 1cm is cut to mouth and nose direction, expose ION, be separated surrounding tissue, loosen ligation with two 4.0 chromium lines, two lines are 2mm apart, ligation elasticity requires only to reduce diameter nerve (naked eyes or microscope under) to postpone nerve conduction, but can not block its conduction completely and blood circulation must be unobstructed; Postoperative 4.0 silk suture otch.All operations all aseptically carries out, and preoperative and postoperative is without the need to applying antibiotic.
2, grouping and administration
Be divided into five groups (n=10 is only) to test by complete random packet principle, each group gives following medicine respectively:
Model group: the isopyknic normal saline of gavage;
Carbamazepine group: gavage gives carbamazepine 20.0mg/kg;
Chinese medicine high group: gavage gives Chinese medicine composition 0.5g/kg described in the embodiment of the present invention 2;
Group in Chinese medicine: gavage gives Chinese medicine composition 2mg/kg described in the embodiment of the present invention 2;
Low group of Chinese medicine: gavage gives the 8mg/kg of the Chinese medicine composition described in the embodiment of the present invention 2;
Each group of successive administration 14 days, the behavior reaction of rat and pain threshold after record administration.
4, observation item
Animal behavioral study with must pad portion on the left of mechanical threshold tester stimulation in rats, records PT trend over time after preoperative Basic Pain Threshold, the behavior reaction of postoperative 2 weeks rats and pain threshold (Painthreshold, PT) and medication.Mechanical stimulus intensity needs from small to large, when Mus occurs that following any one behavioristics changes, record the intensity used, this intensity is its pain threshold (according to the standard that Juhana etc. formulates, following behavior is top score in the behavior reaction integrating system of Vos, represents maximum injury behavior).
(1) withdrawing reaction, Animal performance is head retrude rapidly; (2) to run away or aggressive behavior, show as and flee from, roll up, hide head or sting, grab stimulus object; (3) asymmetry scratches face behavior, namely pays no attention to disconnected more than at least 3 times washing one's face to stimulation location or scratches face outbreak; (4) if when stimulus intensity is 26g, rat does not occur that above any one is reacted, and pain threshold is decided to be 26g.If the behavior reaction that stimulus intensity shows for rat during n is non-constant, and constant when stimulus intensity is n+1, then pain threshold is 2n+1/2.
5, experimental result and analysis
After two treated animal mechanical stimuluss survey pain threshold mean+SD and represent, data analysis is carried out in repeated measure variance analysis and the t inspection of application SPSS11.0 software, and P<0.05 is for having statistical significance.
Table 2 Chinese medicine composition of the present invention is to the therapeutical effect of trigeminal neuralgia of rats model
Compare with model group, *p < 0.05, *p < 0.01;
Compare with carbamazepine group, ＄p < 0.05, ＄ ＄p < 0.01;
Experimental result is as shown in Table 2 known, all there is significant rising the threshold of pain of the different time sections in carbamazepine group and each traditional Chinese medicine composition for treating group relative to model group, embody prosopalgic therapeutical effect, wherein each dosage group of Chinese medicine has pole significant difference (P < 0.01) compared with model group, also has the difference (P < 0.05) of significance compared with conventional trigeminal neuralgia medicine carbamazepine group.Chinese medicine composition is better at treatment effects in treating trigeminal neuralgia, and presents dose dependent, and Chinese medicine composition of the present invention is to prosopalgic Long term therapy better effects if.

Claims (6)

1. the Chinese medicine composition for the treatment of trigeminal neuralgia and merging sleep disorder, it is characterized in that, it obtains primarily of the raw material of following weight portion: Rhizoma et radix valerianae 15 parts, Radix Angelicae Sinensis 15 parts, Radix Polygoni Multiflori 6 parts, Herba Agrimoniae 10 parts, Herba Ecliptae 10 parts, Folium Ginkgo 6 parts, Semen Ziziphi Spinosae 8 parts, the Radix Angelicae Dahuricae 10 parts, Rhizoma Polygoni Cuspidati 20 parts, Ramulus Cinnamomi 20 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 5 parts, Concha Ostreae 5 parts, Concha Haliotidis 10 parts.
2. Chinese medicine composition as claimed in claim 1, it is characterized in that, described Chinese medicine composition contains 6 parts, Radix Rehmanniae Preparata, Herba Epimedii 12 parts and Galla Chinensis 8 parts.
3. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that, described Chinese medicine composition is mixture, tablet or capsule.
4. prepare the method for Chinese medicine composition as claimed in claim 1 or 2 for one kind, it is characterized in that, it comprises the following steps: get each medical material, add the 5-15 water doubly of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate reduced in volume is to the extractum of relative density 1.05-1.25, and this relative density is testing result at 60 c, and adding ethanol to alcohol content is 60-90%(v/v), leave standstill 24 hours, get supernatant, reclaim ethanol to concentrated, to obtain final product.
5. Chinese medicine composition as claimed in claim 1 or 2 merges the purposes in sleep disorder remedies at preparation treatment trigeminal neuralgia.
6. purposes as claimed in claim 5, is characterized in that, described sleep disorder is the sleep disorder of trigeminal neuralgia initiation or the sleep disorder of Nervous and Mental Factors initiation.
CN201410847968.8A 2014-12-31 2014-12-31 Treat trigeminal neuralgia and merge Chinese medicine composition of sleep-disorder and preparation method thereof Expired - Fee Related CN104547111B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410847968.8A CN104547111B (en) 2014-12-31 2014-12-31 Treat trigeminal neuralgia and merge Chinese medicine composition of sleep-disorder and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410847968.8A CN104547111B (en) 2014-12-31 2014-12-31 Treat trigeminal neuralgia and merge Chinese medicine composition of sleep-disorder and preparation method thereof

Publications (2)

Publication Number Publication Date
CN104547111A true CN104547111A (en) 2015-04-29
CN104547111B CN104547111B (en) 2017-07-28

Family

ID=53064882

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410847968.8A Expired - Fee Related CN104547111B (en) 2014-12-31 2014-12-31 Treat trigeminal neuralgia and merge Chinese medicine composition of sleep-disorder and preparation method thereof

Country Status (1)

Country Link
CN (1) CN104547111B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549104A (en) * 2008-04-03 2009-10-07 北京中科仁和科技有限公司 Traditional Chinese medicine composition for treating trigeminal neuralgia and preparation method thereof
CN103720823A (en) * 2012-10-11 2014-04-16 王宪凯 Traditional Chinese medicine decoction for treating trigeminal neuralgia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101549104A (en) * 2008-04-03 2009-10-07 北京中科仁和科技有限公司 Traditional Chinese medicine composition for treating trigeminal neuralgia and preparation method thereof
CN103720823A (en) * 2012-10-11 2014-04-16 王宪凯 Traditional Chinese medicine decoction for treating trigeminal neuralgia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
草雨田: "失眠症与非处方药", 《科学养生》 *
陈家冠等: "定痛汤治疗原发性三叉神经痛30例疗效观察", 《河北中医》 *

Also Published As

Publication number Publication date
CN104547111B (en) 2017-07-28

Similar Documents

Publication Publication Date Title
CN103386008B (en) Chinese medicine composition for treating endocrine dyscrasia
CN103386088B (en) Chinese medicine composition for treating insomnia
CN101011549A (en) Medicament for nourishing liver and kidney, strengthening brain and developing intelligence and its preparation method
CN103550495B (en) A kind of Chinese medicine composition of Cure for insomnia
CN107715067B (en) Pharmaceutical composition for conditioning blood stasis constitution and preparation method and application thereof
CN102631579B (en) Oral Chinese herbal preparation for treating post-traumatic brain syndrome
CN104888131A (en) Traditional Chinese medicine composition for treatment of insomnia
CN101856487A (en) Chinese medicament for treating insomnia
CN103211962A (en) Chinese medicinal composition for treating anhypnia
CN103356932B (en) A kind of pharmaceutical composition for the treatment of vulva squamous epithelial hyperplasia
CN105456818A (en) Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition
CN104189769A (en) Traditional Chinese medicine composition for treating sleep disorders and preparation method thereof
CN105311140A (en) Pharmaceutical composition for treating cervical spondylosis and preparation method thereof
CN104758674A (en) Traditional Chinese medicine composition for treating insomnia
CN104547111A (en) Traditional Chinese medicinal composition for treating prosopalgia and induced sleep disorders and method for preparing composition
CN104758652A (en) Traditional Chinese medicine composition for treating dizziness
CN103736011B (en) Injection care drug of a kind of cholesterol reducing and preparation method thereof
CN104435437B (en) A kind ofly treat Chinese medicine of the concurrent glossopharyngeal neuralgia of trigeminal neuralgia and preparation method thereof
CN104548020A (en) Application of medicine composition in preparing medicine curing senile dementia
CN104547422A (en) New use of traditional Chinese medicine composition
CN103816343A (en) Traditional Chinese medicine composition for treating head ring of old people
CN103735829A (en) Traditional Chinese medicine composition for treating spontaneous perspiration
CN103330896B (en) Preparation method of powder for treating postpartum nonspecific vaginitis
CN103110743B (en) Traditional Chinese medicine composition for treating or preventing neurasthenia and preparation method thereof
CN103301374B (en) Pharmaceutical composition for treating postpartum non-specificity vaginitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170728

Termination date: 20181231